HC Surgical Specialists’ FY2019 Profit Attributable to Shareholders Increased 61% to S$7.2 million
- Profit attributable to shareholders rose 61% to S$7.2 million on the back of a 14% rise in revenue due to increased contributions from both new and existing subsidiaries
- Proposes final dividend of 1.2 Singapore cents per share. In addition to the interim dividend of
1.0 Singapore cents per share, aggregate dividend will be 2.2 Singapore cents per share for
FY2019, a 4.8% increase from the prior year
- Exclusive collaboration with AIA Singapore for colorectal cancer screening for initial term of 3
Singapore, 25 July 2019 – Catalist-listed HC Surgical Specialists Limited (SGX:1B1) (“HCSS”, or collectively with its subsidiaries and associated companies, the “Group”) today announced its financial results for the financial year ended 31 May 2019 (“FY2019”).
The Directors are recommending a final dividend of 1.2 Singapore cents, subject to shareholders’ approval at the forthcoming Annual General Meeting to be convened. Prior to this, the Group has also paid an interim dividend of 1.0 Singapore cents per share in January 2019. In aggregate, total dividend for FY2019 amount to 2.2 Singapore cents per share, a 4.8% increase from the prior year.
Another Record Year
“It has been a fruitful year for us in FY2019, as we continue to extend our footprint in Singapore with investments in Nuffield Dental Holdings – diversifying our business across specialties and expanding our network of GPs. Towards the end of the financial year, we were also appointed as AIA’s exclusive colorectal cancer screening provider for their eligible policy holders. This is a testament to the quality of our service and the growing reputation of our specialists. The appointment is expected to generate an additional recurring revenue stream and broaden our network for patient referrals.” said Group Chief Executive Officer, Dr. Heah Sieu Min.